Cooper Companies [COO] vs ResMed [RMD] Detailed Stock Comparison
Cooper Companies
NASDAQ
Loading...
ResMed
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Cooper Companies wins in 6 metrics, ResMed wins in 13 metrics, with 0 ties. ResMed appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Cooper Companies | ResMed | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 35.39 | 30.11 | ResMed |
| Price-to-Book Ratio | 1.76 | 7.02 | Cooper Companies |
| Debt-to-Equity Ratio | 31.19 | 14.27 | ResMed |
| PEG Ratio | -19.97 | 27.80 | Cooper Companies |
| EV/EBITDA | 15.21 | 22.32 | Cooper Companies |
| Profit Margin (TTM) | 10.39% | 27.22% | ResMed |
| Operating Margin (TTM) | 18.44% | 33.87% | ResMed |
| EBITDA Margin (TTM) | 18.44% | 33.87% | ResMed |
| Return on Equity | 5.15% | 25.86% | ResMed |
| Return on Assets (TTM) | 3.88% | 14.02% | ResMed |
| Free Cash Flow (TTM) | $288.10M | $1.65B | ResMed |
| Dividend Yield | N/A | 0.63% | N/A |
| 1-Year Return | -22.81% | 27.22% | ResMed |
| Price-to-Sales Ratio (TTM) | 3.66 | 8.14 | Cooper Companies |
| Enterprise Value | $17.09B | $41.52B | ResMed |
| EV/Revenue Ratio | 4.28 | 8.07 | Cooper Companies |
| Gross Profit Margin (TTM) | 67.75% | 60.84% | Cooper Companies |
| Revenue per Share (TTM) | $20 | $35 | ResMed |
| Earnings per Share (Diluted) | $2.07 | $9.50 | ResMed |
| Beta (Stock Volatility) | 1.00 | 0.77 | ResMed |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Cooper Companies vs ResMed Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Cooper Companies | 3.00% | -0.54% | 2.41% | -7.98% | -17.45% | -19.44% |
| ResMed | 1.87% | 1.27% | 10.45% | 17.32% | 24.45% | 26.20% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Cooper Companies | -22.81% | -1.48% | -7.51% | 77.32% | 633.33% | 336.06% |
| ResMed | 27.22% | 30.38% | 59.98% | 449.53% | 842.60% | 1,491.28% |
Performance & Financial Health Analysis: Cooper Companies vs ResMed
| Metric | COO | RMD |
|---|---|---|
| Market Information | ||
| Market Cap | $14.62B | $41.88B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,507,780 | 938,310 |
| 90 Day Avg. Volume | 2,072,487 | 1,062,973 |
| Last Close | $75.23 | $293.73 |
| 52 Week Range | $65.00 - $112.38 | $199.92 - $293.81 |
| % from 52W High | -33.06% | -0.03% |
| All-Time High | $115.90 (Aug 30, 2021) | $301.34 (Sep 06, 2021) |
| % from All-Time High | -35.09% | -2.53% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.06% | 0.10% |
| Quarterly Earnings Growth | -0.01% | 0.30% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.27% |
| Operating Margin (TTM) | 0.18% | 0.34% |
| Return on Equity (TTM) | 0.05% | 0.26% |
| Debt to Equity (MRQ) | 31.19 | 14.27 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $41.54 | $40.77 |
| Cash per Share (MRQ) | $0.58 | $8.26 |
| Operating Cash Flow (TTM) | $762.40M | $1.75B |
| Levered Free Cash Flow (TTM) | $228.08M | $1.21B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.63% |
| Last 12-Month Dividend | $0.00 | $1.59 |
Valuation & Enterprise Metrics Analysis: Cooper Companies vs ResMed
| Metric | COO | RMD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 35.39 | 30.11 |
| Forward P/E | 17.96 | 27.80 |
| PEG Ratio | -19.97 | 27.80 |
| Price to Sales (TTM) | 3.66 | 8.14 |
| Price to Book (MRQ) | 1.76 | 7.02 |
| Market Capitalization | ||
| Market Capitalization | $14.62B | $41.88B |
| Enterprise Value | $17.09B | $41.52B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.28 | 8.07 |
| Enterprise to EBITDA | 15.21 | 22.32 |
| Risk & Other Metrics | ||
| Beta | 1.00 | 0.77 |
| Book Value per Share (MRQ) | $41.54 | $40.77 |
Financial Statements Comparison: Cooper Companies vs ResMed
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | COO | RMD |
|---|---|---|
| Revenue/Sales | $1.00B | $1.35B |
| Cost of Goods Sold | $323.20M | $527.93M |
| Gross Profit | $679.10M | $820.07M |
| Research & Development | $45.50M | $86.44M |
| Operating Income (EBIT) | $184.80M | $456.57M |
| EBITDA | $262.50M | $532.89M |
| Pre-Tax Income | $144.50M | $458.05M |
| Income Tax | $56.80M | $78.35M |
| Net Income (Profit) | $87.70M | $379.71M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | COO | RMD |
|---|---|---|
| Cash & Equivalents | $116.20M | $1.21B |
| Total Current Assets | $2.13B | $3.51B |
| Total Current Liabilities | $1.01B | $1.02B |
| Long-Term Debt | $2.53B | $811.41M |
| Total Shareholders Equity | $8.29B | $5.97B |
| Retained Earnings | $7.46B | $6.08B |
| Property, Plant & Equipment | N/A | $288.62M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | COO | RMD |
|---|---|---|
| Operating Cash Flow | $261.80M | $441.40M |
| Capital Expenditures | $-78.10M | $-30.59M |
| Free Cash Flow | $18.10M | $504.99M |
| Debt Repayment | $-714.60M | $-5.00M |
| Common Stock Repurchase | N/A | $-100.01M |
Short Interest & Institutional Ownership Analysis
| Metric | COO | RMD |
|---|---|---|
| Shares Short | 7.16M | 9.02M |
| Short Ratio | 2.98 | 9.55 |
| Short % of Float | 0.04% | 0.07% |
| Average Daily Volume (10 Day) | 1,507,780 | 938,310 |
| Average Daily Volume (90 Day) | 2,072,487 | 1,062,973 |
| Shares Outstanding | 199.60M | 146.39M |
| Float Shares | 198.22M | 145.51M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.04% | 0.65% |
Dividend Analysis & Yield Comparison: Cooper Companies vs ResMed
| Metric | COO | RMD |
|---|---|---|
| Last 12-Month Dividend | $0.00 | $1.59 |
| Last 12-Month Dividend Yield | N/A | 0.63% |
| 3-Year Avg Annual Dividend | $0.01 | $1.60 |
| 3-Year Avg Dividend Yield | 0.01% | 0.23% |
| 3-Year Total Dividends | $0.03 | $4.79 |
| Ex-Dividend Date | Jul 26, 2023 | Feb 13, 2025 |